Navigation Links
China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Date:8/19/2007

e quarter.

Gross profit increased 18% for the three months ended June 30, 2007 to $2.2 million compared to $1.9 million for the same period in 2006. The gross profit margin for the three months ended June 30, 2007 was 25% compared to 27% for the same period in 2006.

Income from operations for the three months ended June 30, 2007 decreased 25% to $649 thousand compared to $860 thousand for the same period in 2006. The decrease is mainly attributable to high operational expenses and poor operational performance of Enshi of which financials were only partially reflected for the three months ended June 30, 2006.

The Company reported a net loss for the second quarter of 2007 of $29 thousand compared to a net income of $391 thousand for the second quarter of 2006. The net loss for the quarter was mainly attributable to the higher payment and accrued interest expenses as a result of the acquisition financing loan due to RimAsia Capital Partners for Enshi. EBITDA for the second quarter of 2007 decreased 25% to $945 thousand compared to $1.2 million for the same period in 2006.

As of June 30, 2007, total assets were $50 million and total liabilities were $36.7 million. Shareholder equity was $13.4 million or $.37 per share.

Ms. ZHANG Jian, Chairwoman of the Board, commented, "This quarter the management team and I have been focused on restructuring our balance sheet and building our core business, especially our most successful subsidiary, Erye. Recently, we signed a letter of intent with RimAsia to convert their $11.5 million of debt to equity. I can assure our shareholders that we are working diligently to ensure these negotiations become finalized in a timely fashion."

Ms. ZHANG Jian, continued, "I am also pleased to announce our intent to acquire the remaining 49% of Erye. With the continued success of Erye this quarter and the strong growth potential of this subsidiary, the team and I are eager to finalize the acquisition of the remai
'/>"/>

SOURCE China Biopharmaceuticals Holdings, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. How do you level the playing field with China?
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GEA Niro Soavi the leader in high pressure ... 2000, which is ideal for new applications for processing ... . This compact laboratory homogenizer is the perfect solution ... additives and ingredients as well as for the ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... 22, 2015 Dr. Greg Leyer of UAS ... Scripps Natural Supplements Pre-Conference seminar on probiotics in San Diego, ... annual continuing education conference for health care professionals. This year’s ... topic of probiotics in health. Dr. Leyer spoke about the ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... Purpose , ... the new Q TRAP LC/MS/MS system with Metabolite ID software for Phase ... increase your productivity and confidence in your results. , ... Current trends in drug development are placing more emphasis on ...
... Jason S. Wood, Varian, Inc. , ... Cytochrome P450s (CYPs) are heme-containing ... 1 . CYPs are part of the Phase I (oxidative) metabolism ... drug enabling either easy elimination of the drug or further conjugation ...
... , Z. Yang and S. ... Introduction , Amphetamine ... place, and by recreational users. Forensic, clinical, and doping laboratories are ... Urine samples are most common because large sample volumes can be ...
Cached Biology Technology:Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 2Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 3Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 4Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 5Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 2Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 3Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS 2Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS 3
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... a major role in a NASA mission, which they believe ... surface of a comet. , NASA's Deep Impact spacecraft will ... when a metre-long projectile will crash into the comet and ... plume of gas and dust. , UK astronomers involved in ...
... Society of Conservation Biology annual meetings, in Brasília, Brazil, ... Pesquisa Ambiental da Amazonia (IPAM) will hold an international ... resources in the Amazon Basin. , This region has ... the principle industries driving deforestation (cattle ranching and soybean ...
... at U.S. ports, a public enemy has infiltrated the nation's ... a Cornell University expert, the adult female alien is the ... United States. , The discovery of a single specimen of ... across the nation because the invasive insect species has devastated ...
Cached Biology News:NASA probe could reveal comet life, scientists claim 2Alien woodwasp, threat to US pine trees, found in N.Y. 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
...
...
Biology Products: